Cardio Diagnostics Holdings Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cardio Diagnostics Holdings Inc.
- Former names
- Mana Capital Acquisition Corp.
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Chicago
- Headquarters state / province
- Illinois
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CDIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001870144
- EIN
- 87-0925574
Board of directors
-
Brandon Sim · DirectorSince 2023
-
James Intrater · DirectorSince 2023
-
Meeshanthini Dogan · Director · Chief Executive OfficerSince 2023
-
Oded Levy · DirectorSince 2023
-
Paul Frederick Burton · DirectorSince 2023
-
Peter K. Fung · DirectorSince 2024
-
Robert Philibert · Director · Chief Medical OfficerSince 2023
-
Stanley K. Lau · DirectorSince 2023
-
Warren Hosseinion · DirectorSince 2023
-
Wendy J. Betts · DirectorSince 2024
Chief executives
Meeshanthini Dogan
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of September 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.2%
-
87.0%
-
87.2%
-
87.9%
-
88.1%
-
88.9%
-
89.0%
Board connections
1 of this board's directors also sit on 3 other boards.
- via Warren Hosseinion
- via Warren Hosseinion
- via Warren Hosseinion
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 6, 2024 | Robert Philibert Director, Officer (Chief Medical Officer) | Open-market purchase | +26,615 | $0.29 | $7,718 |
| Sep 6, 2024 | Meeshanthini Dogan Officer (Chief Technology Officer) | Open-market purchase | +68,965 | $0.29 | $20,000 |
| Sep 6, 2024 | Meeshanthini Dogan Director, Officer (Chief Executive Officer) | Open-market purchase | +68,965 | $0.29 | $20,000 |
| Sep 6, 2024 | Robert Philibert Director, Officer (Chief Medical Officer) | Open-market purchase | +7,460 | $0.28 | $2,089 |
| Mar 31, 2024 | Paul Frederick Burton Director | Option exercise | +8,803 | $1.42 | $12,500 |
| Mar 31, 2024 | Stanley K. Lau Director | Option exercise | +8,803 | $1.42 | $12,500 |
| Mar 31, 2024 | James Intrater Director | Option exercise | +8,803 | $1.42 | $12,500 |
| Mar 31, 2024 | Oded Levy Director | Option exercise | +8,803 | $1.42 | $12,500 |
| Jan 31, 2024 | Stanley K. Lau Director | Option exercise | +917 | $2.18 | $1,999 |
| Dec 31, 2023 | Brandon Sim Director | Option exercise | +5,020 | $2.49 | $12,500 |
| Dec 31, 2023 | James Intrater Director | Option exercise | +5,020 | $2.49 | $12,500 |
| Dec 31, 2023 | Oded Levy Director | Option exercise | +5,020 | $2.49 | $12,500 |
| Dec 31, 2023 | Stanley K. Lau Director | Option exercise | +1,606 | $2.49 | $3,999 |
| Dec 31, 2023 | Stanley K. Lau Director | Option exercise | +5,020 | $2.49 | $12,500 |
| Oct 31, 2023 | Stanley K. Lau Director | Option exercise | +6,631 | $0.30 | $1,989 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.